Publications by authors named "Percy Carter"

Claim this Profile
C
Challenges with the Synthesis of a Macrocyclic Thioether Peptide: From Milligram to Multigram Using Solid Phase Peptide Synthesis (SPPS).
James Kempson, Rulin Zhao, Joseph Pawluczyk, Bei Wang, Huiping Zhang, Percy H Carter

J Org Chem· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5.
John R D Dawson, Grant M Wadman, Penglie Zhang, Andrew Tebben, Percy H Carter

bioRxiv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of macrocyclic peptide binders to the extracellular CRD domain of human receptor tyrosine kinase-like orphan receptor 1 (ROR1).
Jennifer X Qiao, Mark R Witmer, Ving Lee, Tammy C Wang, Patrick C Reid, Percy Carter

Bioorg Med Chem Lett· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variations.
Zili Xiao, Michael G Yang, Chunjian Liu, Trevor Sherwood, John L Gilmore, Percy H Carter

Bioorg Med Chem Lett· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8).
Ratna Kumar Sreekantha, Christopher P Mussari, Dharmpal S Dodd, Laxman Pasunoori, Subramanya Hegde, Percy H Carter

ACS Med Chem Lett· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate.
Robert J Cherney, Prakash Anjanappa, Kumaravel Selvakumar, Douglas G Batt, Gregory D Brown, Percy H Carter

ACS Med Chem Lett· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.
Michael G Yang, Zili Xiao, Rulin Zhao, Andrew J Tebben, Bei Wang, Percy H Carter

ACS Med Chem Lett· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bicyclic Ligand-Biased Agonists of S1P: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles.
John L Gilmore, Hai-Yun Xiao, T G Murali Dhar, Michael Yang, Zili Xiao, Percy H Carter

J Med Chem· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.
Chunjian Liu, James Lin, Charles Langevine, Daniel Smith, Jianqing Li, Percy H Carter

J Med Chem· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK.
Anurag S Srivastava, Soo Ko, Scott H Watterson, Mark A Pattoli, Stacey Skala, Percy H Carter

ACS Med Chem Lett· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2,6-difluorobenzyl ether series of phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfones as surprisingly potent, selective and orally bioavailable RORγt inverse agonists.
James J-W Duan, Bin Jiang, Zhonghui Lu, Sylwia Stachura, Carolyn A Weigelt, Percy H Carter

Bioorg Med Chem Lett· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonists.
Bin Jiang, James J-W Duan, Sylwia Stachura, Ananta Karmakar, Hemalatha Hemagiri, Percy H Carter

Bioorg Med Chem Lett· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).
Christopher P Mussari, Dharmpal S Dodd, Ratna Kumar Sreekantha, Laxman Pasunoori, Honghe Wan, Percy H Carter

ACS Med Chem Lett· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P) Modulators: Optimization of the PK, PD, and Safety Profiles.
Zili Xiao, Michael G Yang, T G Murali Dhar, Hai-Yun Xiao, John L Gilmore, Percy H Carter

ACS Med Chem Lett· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis.
Satheesh Nair, Sreekantha Ratna Kumar, Venkatram Reddy Paidi, Ramesh Sistla, Durgarao Kantheti, Percy H Carter

ACS Med Chem Lett· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist.
Robert J Cherney, Lyndon A M Cornelius, Anurag Srivastava, Carolyn A Weigelt, David Marcoux, Percy H Carter

ACS Med Chem Lett· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy.
David Marcoux, James J-W Duan, Qing Shi, Robert J Cherney, Anurag S Srivastava, Percy H Carter

J Med Chem· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of -Methyl Nicotinamide and -Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2).
Ryan Moslin, Yanlei Zhang, Stephen T Wrobleski, Shuqun Lin, Michael Mertzman, Percy H Carter

J Med Chem· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
Stephen T Wrobleski, Ryan Moslin, Shuqun Lin, Yanlei Zhang, Steven Spergel, Percy H Carter

J Med Chem· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.
Zhonghui Lu, James J-W Duan, Haiyun Xiao, James Neels, Dauh-Rurng Wu, Percy H Carter

Bioorg Med Chem Lett· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
Scott H Watterson, Qingjie Liu, Myra Beaudoin Bertrand, Douglas G Batt, Ling Li, Percy H Carter

J Med Chem· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672.
Michael G Yang, Zili Xiao, Robert J Cherney, Andrew J Tebben, Douglas G Batt, Percy H Carter

ACS Med Chem Lett· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis.
Steven H Spergel, Michael E Mertzman, James Kempson, Junqing Guo, Sylwia Stachura, Percy H Carter

ACS Med Chem Lett· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists.
James J-W Duan, Zhonghui Lu, Bin Jiang, Sylwia Stachura, Carolyn A Weigelt, Percy H Carter

ACS Med Chem Lett· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Imidazo[1,2-]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.
Chunjian Liu, James Lin, Ryan Moslin, John S Tokarski, Jodi Muckelbauer, Percy H Carter

ACS Med Chem Lett· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis